AMRx AMRX アムニ―ル・ファ―マシュ―ティカルズ



symbol AMRx
会社名 Amneal Pharmaceuticals Inc (AMRX アムニ―ル・ファ―マシュ―ティカルズ)
業種 医薬品   医療関連(Health Care)
概要 事業概要 アムニール・ファーマシューティカルズ(Amneal Pharmaceuticals Inc.)は専門医薬会社である。同社は、ブランド製品の開発・マーケティング、及び生物学的同等医薬品(ジェネリック医薬品)の開発・製造・販売に従事する。同社は2つの事業セグメントを運営する。Impaxジェネリックスは、ブランド名の医薬品医薬品および治療剤と同等の薬品名で販売されている同社のジェネリック医薬品の開発・製造・販売・流通に従事する。Impax専門製薬事業は、パーキンソン病(PD)、脳炎後パーキンソニズムおよびパーキンソニズムの治療用カルビドパ - レボドパの持続放出経口カプセル製剤であるRytary等のブランド医薬品、並びに片頭痛の治療に適応されたゾミグ(ゾルミトリプタン)製品を含む複数のブランド製品の宣伝・販売・流通に従事する。  インパックス・ラボラトリ―ズは、米国の製薬会社。ジェネリック医薬品の開発、製造、販売、流通を中心に行うほか、片頭痛、多発性硬化症、パ―キンソン病、帯状疱疹後の神経痛など中枢神経系障害の治療のため自社ブランド医薬品の開発を手掛ける。主要製品は「Adderall XR」、「Trilipix」、「RYTARY」など。  Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
本社所在地 908 947-3120
代表者氏名 Paul M. Bisaro
代表者役職名 Executive Chairman of the Board
電話番号 +1 908-409-6700
設立年月日 34060
市場名 NYSE(ニューヨーク証券取引所)
従業員数 6000人
EBITDA EBITDA(百万ドル) 373.66200
時価総額 時価総額(百万ドル) 4233.95800
売上高 売上高(百万ドル) 1662.99100
企業価値(EV) 企業価値(EV)(百万ドル) 6711.96000
当期純利益 当期純利益(百万ドル) -21.12000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Amneal Pharmaceuticals Inc revenues increased from $775.8M to $1.66B. Net loss applicable to common stockholders excluding extraordinary items decreased 96% to $21.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects In-process research and development impa decrease of 80% to $39.3M (expense).



   Amneal Pharmaceuticals (NYSE:AMRX) Shares Gap Up After Insider Buying Activity  2021/12/22 06:26:42 Transcript Daily
Amneal Pharmaceuticals, Inc. (NYSE:AMRX)s share price gapped up prior to trading on Monday following insider buying activity. The stock had previously closed at $4.27, but opened at $4.51. Amneal Pharmaceuticals shares last traded at $4.42, with a volume of 11,312 shares traded. Specifically, CEO Chirag K. Patel acquired 100,000 shares of the companys stock in []
   Amneal Pharmaceuticals, Inc. (NYSE:AMRX) CEO Purchases $413,000.00 in Stock  2021/12/20 10:06:45 Dakota Financial News
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) CEO Chirag K. Patel bought 100,000 shares of the companys stock in a transaction that occurred on Wednesday, December 15th. The shares were bought at an average price of $4.13 per share, for a total transaction of $413,000.00. The transaction was disclosed in a legal filing with the SEC, which can []
   Hydroxychloroquine Market Growth in Future Scope 2021-2028 | Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited  2021/12/13 13:17:40 OpenPR
The Hydroxychloroquine Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Hydroxychloroquine Market study includes research on the
   Shoulder Pain Treatment Market Recent Trends, Future Growth Analysis Forecasts 2027| GlaxoSmithKline plc, Contract Pharmacal Corp, Amneal Pharmaceuticals, Inc.  2021/12/10 13:33:11 OpenPR
The global Shoulder Pain Treatment market size is projected to reach US$ 3.6 Billion by 2027, at a CAGR of 8.1% during 2021-2027. Globally, the geriatric population is growing at an unprecedented rate. Shoulder pain is a frequent and debilitating
   TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) Allowing for a May 25, 2032 Generic Entry Date  2021/12/08 11:50:00 Business Wire
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively Amneal). As part of the settlement, TherapeuticsMD granted to Amneal a license to commercialize Amneals generic version of BIJUVA (1 mg estradiol and 100 mg p
   Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Receives $7.40 Consensus Price Target from Analysts  2021/12/02 14:06:42 Transcript Daily
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has received an average recommendation of Buy from the seven research firms that are covering the company, reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target []
   Moving - Amneal Pharmaceuticals, Inc. Given Average Rating of Buy by Brokerages  2021/11/29 06:57:07 Business Mag
Shares of Amneal Pharmaceuticals, Inc. have earned a consensus rating of Buy from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One
   Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Given Average Rating of Buy by Brokerages  2021/11/29 06:50:42 ETF Daily News
Shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) have earned a consensus rating of Buy from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The [] The post Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Given Average Rating of Buy by Brokerages appeared first on ETF Daily News .
   California State Teachers Retirement System Sells 12,187 Shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX)  2021/11/27 10:18:42 Dakota Financial News
California State Teachers Retirement System lessened its stake in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) by 8.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 137,352 shares of the companys stock after selling 12,187 shares during the quarter. California State Teachers Retirement Systems holdings in Amneal []
   Man Group plc Invests $67,000 in Amneal Pharmaceuticals, Inc. (NYSE:AMRX)  2021/11/24 11:32:41 Dakota Financial News
Man Group plc purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) in the second quarter, HoldingsChannel reports. The fund purchased 13,158 shares of the companys stock, valued at approximately $67,000. Several other hedge funds and other institutional investors have also recently modified their holdings of AMRX. Dimensional Fund Advisors LP grew its []
   Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2021 Results - Earnings Call Transcript  2021/08/09 17:23:07 Seeking Alpha
   Amneal Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/09 14:00:35 Seeking Alpha
   The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight  2021/08/08 14:03:32 Benzinga
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week. BeyondSpring Inc. (NASDAQ: BYSI ) was among the biggest biopharma gainers of the week, with the stock reacting to a positive late-stage readout for its lung cancer treatment combo. The stock ended the week with a gain of about 128%. Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA ), however, was not as fortunate, as the stock lost about one-fifth of its market cap following mixed results from a pivotal trial of its RNAi therapeutic candidate nedosiran in primary hyperoxaluria 1. The market reacted negatively to earnings from vaccine companies Moderna, Inc. (NASDAQ: MRNA ) and Novavax, Inc. (NASDAQ: NVAX ). Moderna''s results, although outstanding, elicited negative reaction, while a lack of update about U.S. approval of Novavax'' vaccine sent its shares tumbling on Friday.
   Amneal Receives Approval for Generic TobraDex®  2021/07/19 20:32:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex®, which adds another complex ophthalmic product to the generics portfolio. Dexamethasone and Tobramycin Ophthalmic Suspension 0.3%/0.1% is the generic version of TobraDex®, which is indicated for steroid-responsive inflamm
   Professional Study Report On U.S. Psychedelic Drugs Market Is Expected To Grow At 16.3% In The Forecast Period Of 2020 To 2027||Doughlas pharmaceuticals limited NeuroRX, Inc. Hikma Pharmaceuticals PLC Amneal Pharmaceuticals, LLC. AVADEL PHARMACEUTICALS, P  2021/07/06 09:33:40 OpenPR
U.S. Psychedelic Drugs Market 2021 document provides the most up-to-date market insight and analysis. The key players of the market are making moves like product launches, joint ventures, developments, mergers, and acquisitions which is affecting the market and industry as

 関連キーワード  (医薬品 米国株 AMRX アムニ―ル・ファ―マシュ―ティカルズ AMRX )

 twitter  (公式ツイッターやCEOツイッターなど)